Literature DB >> 12035819

Concentration-targeted therapy and the future of HIV management.

Charles W Flexner, Stephen C Piscitelli.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12035819     DOI: 10.1097/00002030-200203001-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

Review 1.  The role of clinical pharmacology in optimizing antiretroviral therapy.

Authors:  David J Back; Saye H Khoo
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

2.  High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Authors:  Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

Authors:  Robert DiCenzo; Derick Peterson; Kim Cruttenden; Gene Morse; Garret Riggs; Harris Gelbard; Giovanni Schifitto
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  The Role of Therapeutic Drug Monitoring in the Management of HIV-infected Patients.

Authors:  Stephen C. Piscitelli
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

5.  Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.

Authors:  Robert DiCenzo; Derick R Peterson; Kim Cruttenden; Peter Mariuz; Naser L Rezk; Jill Hochreiter; Harris Gelbard; Giovanni Schifitto
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.